|
MURA
|
|
$2.64
* Data may be delayed
|
|
|
COMPANY INFORMATION
Mural Oncology Plc, a clinical-stage oncology company, focuses on discovering and developing immunotherapies for the treatment of patients with cancer.
The company's lead product candidate includes nemvaleukin alfa for the treatment of mucosal melanoma as a monotherapy and platinum-resistant ovarian cancer in combination with pembrolizumab. It also develops engineered interleukin-18 and tumor-targeted interleukin-12 programs. The company was incorporated in 2017 and is based in Dublin, Ireland. As of November 15, 2023, Mural Oncology Plc operates as a former subsidiary of Alkermes plc.. |
INCOME
Calendar Year2024Revenue0 Cost of Revenue0 Gross Profit0 Gross Profit Ratio0 |
|
|
Sponsored By: Benzinga 98767 People Checked This Out
How To Hit More Winning Option Trades
Dear Reader,
There's nothing worse for a new options trader than to…
Guess which option trades to enter.
Do a bunch of work and still make the wrong picks.
And end up wasting a ton of time with little to no gains.
But that doesn't have to happen to you.
Now you can join Options Starter and get 75% off.
Picked for you by Nic Chahine.
The Head of Options Trading at Benzinga.
Who has one of the best track records we know of…
Including recent winning trades like:
90% ROI on JD
511% ROI on AXP
66% ROI on BX
As a member of Options Starter you get:
2 hand-picked option trades per month
Real-time email or SMS entry & exit alerts
Plus a BONUS intro series on option trading
For up to 75% off!
Click Here To Get 75% Off Today!
|
